Natco ties up with Gilead Sciences for Hepatitis C drug

PHARMANacto Pharma has received voluntary licence to manufacture the generic versions of US drug maker Gilead Sciences’ hepatitis C drug Sovaldi. This move leaves the company with one less hurdle to launch the drug in India.


Nacto had filed a pre-grant patent opposition for the drug with the patent office.

This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries. Under the licence, the company can set its own price for the generic products it produces, paying royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top